D-type cyclins (cyclin D1, D2 and D3) are the ultimate recipients of all mitogenic and oncogenic signals. Aberrant expression of D-cyclins is seen in many human malignancies and virtually all human cancers contain lesions in pathways impacting on D-cyclins. We have generated knockout mouse strains lacking cyclin D1, D2 or D3 using homologous recombination in embryonal stem cells. All three strains are viable and display focused, tissue-specific phenotypes. In the proposed work we will use these mice as a tool to study the role of D-cyclins in tumorigenesis. In the first Specific Aim we will ask whether the loss of cyclin D1 renders mice resistant to breast cancers induced by various oncogenes. Cyclin D1 is overexpressed in the majority of human breast cancers. Importantly, overexpression of cyclin D1 is believed to play a causative role in tumorigenesis, as agents that neutralize cyclin D1 function were shown to shut off the proliferation of breast cancer cells in vitro. Cyclin D1 is normally expressed in nearly all human tissues and, until recently, was thought to be indispensable for proliferation of all cell lineages. However, our unexpected finding that in adult cyclin D1-/- mice the consequences of cyclin D1-ablation are restricted to mammary epithelium, raises the possibility that a specific, anti-cyclin D1 therapy for human breast cancers might be highly selective in shutting off the proliferation of tumor cells while sparing other tissues. As a first step towards this goal we wish to test if the ablation of cyclin D1 prevents cancer formation in vivo. In the second Specific Aim we will take advantage of fibroblasts lacking cyclin D1, D2 or D3 to study the dependence of various oncogenic signal transduction pathways on different D-cyclins at the cellular and molecular level. The studies described in the third Specific Aim take advantage of recently-generated cyclin E greater than D1 """"""""knock-in"""""""" mice. In this strain we have deleted the coding exons of cyclin D1 and replaced them by cyclin E cDNA. Analyses of these mice have demonstrated that cyclin E can replace cyclin D1 in driving normal cell proliferation and rescue the phenotypic manifestations of cyclin Dl-deficiency. In this Specific Aim we will ask whether cyclin E can replace cyclin D1 in driving oncogenic growth of cancer cells.
| Geng, Yan; Michowski, Wojciech; Chick, Joel M et al. (2018) Kinase-independent function of E-type cyclins in liver cancer. Proc Natl Acad Sci U S A 115:1015-1020 |
| Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95 |
| Hydbring, Per; Wang, Yinan; Fassl, Anne et al. (2017) Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell 31:576-590.e8 |
| Liu, Lijun; Michowski, Wojciech; Inuzuka, Hiroyuki et al. (2017) G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol 19:177-188 |
| Hydbring, Per; Wang, Yinan; Bogorad, Roman L et al. (2017) Identification of cell cycle-targeting microRNAs through genome-wide screens. Cell Cycle 16:2241-2248 |
| Wang, Haizhen; Nicolay, Brandon N; Chick, Joel M et al. (2017) The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 546:426-430 |
| Otto, Tobias; Candido, Sheyla V; Pilarz, Mary S et al. (2017) Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit. Proc Natl Acad Sci U S A 114:10660-10665 |
| Goel, Shom; Wang, Qi; Watt, April C et al. (2016) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell 29:255-269 |
| Manterola, Marcia; Sicinski, Piotr; Wolgemuth, Debra J (2016) E-type cyclins modulate telomere integrity in mammalian male meiosis. Chromosoma 125:253-64 |
| Zhang, Jinfang; Xu, Kai; Liu, Pengda et al. (2016) Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol Cell 62:929-942 |
Showing the most recent 10 out of 31 publications
